227 related articles for article (PubMed ID: 35313740)
21. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
22. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a
Lipton RB; Tepper SJ; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Zhang F; Rippon GA; Cheng S; Mikol DD
Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
[TBL] [Abstract][Full Text] [Related]
23. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.
Urits I; Jones MR; Gress K; Charipova K; Fiocchi J; Kaye AD; Viswanath O
Curr Pain Headache Rep; 2019 Mar; 23(5):29. PubMed ID: 30874961
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions.
Zhou Y; Zhang F; Starcevic Manning M; Hu Z; Hsu CP; Chen PW; Peng C; Loop B; Mytych DT; Paiva da Silva Lima G
Cephalalgia; 2022 Jul; 42(8):749-760. PubMed ID: 35272533
[TBL] [Abstract][Full Text] [Related]
25. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
26. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Hirata K; Takeshima T; Sakai F; Imai N; Matsumori Y; Tatsuoka Y; Numachi Y; Yoshida R; Peng C; Mikol DD; Lima GPDS; Cheng S
Brain Behav; 2022 Mar; 12(3):e2526. PubMed ID: 35201674
[TBL] [Abstract][Full Text] [Related]
27. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
Wang SJ; Roxas AA; Saravia B; Kim BK; Chowdhury D; Riachi N; Tai MS; Tanprawate S; Ngoc TT; Zhao YJ; Mikol DD; Pandhi S; Wen S; Mondal S; Tenenbaum N; Hours-Zesiger P
Cephalalgia; 2021 Nov; 41(13):1285-1297. PubMed ID: 34171973
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation.
Lowe M; Murray L; Tyagi A; Gorrie G; Miller S; Dani K;
J Headache Pain; 2022 Jul; 23(1):86. PubMed ID: 35869443
[TBL] [Abstract][Full Text] [Related]
29. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
[TBL] [Abstract][Full Text] [Related]
30. A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Becker WJ; Spacey S; Leroux E; Giammarco R; Gladstone J; Christie S; Akaberi A; Power GS; Minhas JK; Mancini J; Rochdi D; Filiz A; Bastien N
Headache; 2022 Apr; 62(4):522-529. PubMed ID: 35403223
[TBL] [Abstract][Full Text] [Related]
31. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
[TBL] [Abstract][Full Text] [Related]
32. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
33. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
[TBL] [Abstract][Full Text] [Related]
34. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
Lipton RB; Tepper SJ; Reuter U; Silberstein S; Stewart WF; Nilsen J; Leonardi DK; Desai P; Cheng S; Mikol DD; Lenz R
Neurology; 2019 May; 92(19):e2250-e2260. PubMed ID: 30996060
[TBL] [Abstract][Full Text] [Related]
35. A prospective real-world analysis of erenumab in refractory chronic migraine.
Lambru G; Hill B; Murphy M; Tylova I; Andreou AP
J Headache Pain; 2020 Jun; 21(1):61. PubMed ID: 32487102
[TBL] [Abstract][Full Text] [Related]
36. [The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].
Dobrynina LA; Gubanova MV; Belopasova AV; Baydina EV; Afanasev MA
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(2):74-80. PubMed ID: 35271240
[TBL] [Abstract][Full Text] [Related]
37. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study.
Lanteri-Minet M; Fabre R; Martin C; Pradat K; Alchaar A; Bozzolo E; Duchene ML; Van Obberghen EK; Donnet A; Fontaine D
J Headache Pain; 2023 Nov; 24(1):152. PubMed ID: 37940860
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis.
Fernández-Bravo-Rodrigo J; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Flor-García A; Barreda-Hernández D; Pascual-Morena C
Eur J Pharmacol; 2024 Aug; 976():176702. PubMed ID: 38823758
[TBL] [Abstract][Full Text] [Related]
39. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
Eghtesadi M; Leroux E; Pagé G
Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
[TBL] [Abstract][Full Text] [Related]
40. Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17-30 months.
Troy E; Shrukalla AA; Buture A; Conaty K; Macken E; Lonergan R; Melling J; Long N; Shaikh E; Birrane K; Tomkins EM; Goadsby PJ; Ruttledge MH
J Headache Pain; 2023 Jan; 24(1):5. PubMed ID: 36647006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
